Abstract
Recently, a group of microRNAs (miRNAs), the miR-200 family (miR-200s) has been found to be deregulated in multiple types of cancers, in which this family of miRNAs was demonstrated to play a pivotal role in tumor initiation, maintenance, malignant metastasis and chemotherapy resistance. By targeting several central inducers of the epithelial-to-mesenchymal transition (EMT), e.g. ZEB1, ZEB2 and SLUG, miR-200s are currently recognized as master regulators of EMT, thereby suppressing cancer invasion and metastasis. The involvement of miR-200s in angiogenesis has also been reported, and they were found to directly target VEGF-A, FLT1/VEGFR1 and KDR/VEGFR2, three key components of the VEGF signaling pathway. Importantly, miR-200s also modulate the self-renewal ability of cancer stem cells by targeting BMI1 and SUZ12. Aberrant expression of miR-200s has been shown to confer chemoresistant properties to various kinds of cancers. Thus, miR-200s, by playing critical and pleiotropic roles in malignancies, are promising targets for cancer therapy. Notably, it has been shown that several types of natural agents and herbal extracts could be employed to manipulate the expression of miR-200s, making the targeting of miR-200s in cancer therapy more clinically attractive. Nevertheless, a very recent study reported a metastasis-promoting role of miR-200s in breast cancer; thus, careful assessment should be conducted before applying therapeutic interventions using miR-200s as treatment targets. In this review, we will focus on our emerging understanding of the roles of miR- 200s in cancer, specifically their therapeutic potential in treating cancer.
Keywords: miR-200 family, epithelial-to-mesenchymal transition, tumor metastasis, cancer stem cells, angiogenesis, cancer therapeutics.
Current Pharmaceutical Design
Title:A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Volume: 20 Issue: 11
Author(s): Hai-Feng Zhang, Li-Yan Xu and En-Min Li
Affiliation:
Keywords: miR-200 family, epithelial-to-mesenchymal transition, tumor metastasis, cancer stem cells, angiogenesis, cancer therapeutics.
Abstract: Recently, a group of microRNAs (miRNAs), the miR-200 family (miR-200s) has been found to be deregulated in multiple types of cancers, in which this family of miRNAs was demonstrated to play a pivotal role in tumor initiation, maintenance, malignant metastasis and chemotherapy resistance. By targeting several central inducers of the epithelial-to-mesenchymal transition (EMT), e.g. ZEB1, ZEB2 and SLUG, miR-200s are currently recognized as master regulators of EMT, thereby suppressing cancer invasion and metastasis. The involvement of miR-200s in angiogenesis has also been reported, and they were found to directly target VEGF-A, FLT1/VEGFR1 and KDR/VEGFR2, three key components of the VEGF signaling pathway. Importantly, miR-200s also modulate the self-renewal ability of cancer stem cells by targeting BMI1 and SUZ12. Aberrant expression of miR-200s has been shown to confer chemoresistant properties to various kinds of cancers. Thus, miR-200s, by playing critical and pleiotropic roles in malignancies, are promising targets for cancer therapy. Notably, it has been shown that several types of natural agents and herbal extracts could be employed to manipulate the expression of miR-200s, making the targeting of miR-200s in cancer therapy more clinically attractive. Nevertheless, a very recent study reported a metastasis-promoting role of miR-200s in breast cancer; thus, careful assessment should be conducted before applying therapeutic interventions using miR-200s as treatment targets. In this review, we will focus on our emerging understanding of the roles of miR- 200s in cancer, specifically their therapeutic potential in treating cancer.
Export Options
About this article
Cite this article as:
Zhang Hai-Feng, Xu Li-Yan and Li En-Min, A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets, Current Pharmaceutical Design 2014; 20 (11) . https://dx.doi.org/10.2174/13816128113199990519
DOI https://dx.doi.org/10.2174/13816128113199990519 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Equibiotic-GI Consumption Improves Intestinal Microbiota in Subjects with Functional Dyspepsia
Current Drug Therapy Gut Emotions - Mechanisms of Action of Probiotics as Novel Therapeutic Targets for Depression and Anxiety Disorders
CNS & Neurological Disorders - Drug Targets Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Strategies for Design of Non Peptide CCK1R Agonist/Antagonist Ligands
Current Topics in Medicinal Chemistry In vivo Fluorescence Detection in Surgery: A Review of Principles, Methods, and Clinical Applications
Current Medical Imaging Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Theoretical Modelling of Potential Chk1 Inhibitors
Letters in Drug Design & Discovery Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Role of Chromatography for Monitoring of Breast Cancer Biomarkers
Recent Patents on Biomarkers Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients’ Outcome
Current Cancer Drug Targets Glioblastoma Targeted Gene Therapy Based on pEGFP/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles
Current Gene Therapy Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Subject Index To Volume 1
Current Gene Therapy